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INTRODUCTION
Since 1997, the National Birth Defects Prevention Network (NBDPN), in collaboration with 
the Centers for Disease Control and Prevention (CDC), has published data on major birth 
defects affecting the central nervous, eye, ear, cardiovascular, orofacial, gastrointestinal, 
genitourinary, and musculoskeletal systems, as well as trisomies, amniotic bands, and fetal 
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alcohol syndrome, from population-based birth defects surveillance programs in the United 
States. Annually, the NBDPN Data Committee issues a data request to population-based 
birth defects programs for data on 47 major birth defects; the specific defects with 
accompanying diagnostic codes are detailed in Appendix 1 on page 10. This year’s report 
containing data from 41 population-based birth defects surveillance programs for births 
occurring from January 1, 2005, through December 31, 2009, is available as a supplement 
on pages. The data are presented by racial/ethnic groups for all defects and additionally by 
maternal age for triso-mies 13, 18, and 21.
To calculate prevalence, programs were also asked to provide the number of total live births 
and male live births for each calendar year submitted. The standard method for calculating 
birth defects prevalence is to divide the number of cases (birth defect for any pregnancy 
outcome) by total live births for the catchment area and then multiply by 10,000 to obtain 
the prevalence per 10,000 live births; Mason et al. (2005) provide further detail and rationale 
for this approach. This methodology is used for all defects except hypospadias, which is 
calculated using a denominator of total male live births. An attempt was made to standardize 
both the submitted data and presentation of state surveillance data, however, differences in 
the way programs collect and report birth defects data are listed in the footnotes of the 
accompanying tables and may be referenced in the program directories on pages S121-S169 
(online). Some programs were able to only provide data for selected years, were unable to 
report counts and prevalence by race/ethnicity, or were unable to provide data for each 
specific defect requested due to differences in the coding systems (i.e., International 
Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] vs CDC/British 
Pediat-ric Association [BPA]) Classification of Diseases used to classify birth defects.
Critical Congenital Heart Defects Targeted for Pulse Oximetry Screening
This year’s data report includes several enhancements to address the interest in pulse 
oximetry screening of new-borns for critical congenital heart defects (CCHDs). Congenital 
heart defects (CHDs) occur in an estimated 1 in 110 births in the United States (Reller et al., 
2008) and approximately 25% of CHDs are considered CCHDs, defined as requiring surgery 
or catheter intervention within the first year of life (Mahle et al., 2009). Children with 
CCHDs are at risk for death or disability if the defect is not detected shortly after birth 
(Mahle et al., 2009). Thus, in 2011, the Secretary of Health and Human Services 
recommended that CCHDs be added to the U.S. Recommended Uniform Screening Panel 
for newborns (Secretary’s Advisory Committee on Heritable Disorders in Newborns and 
Children, 2011). When implemented, newborns would undergo pulse oximetry screening for 
CCHDs after 24 hours of life, which detects low blood oxygen levels (hypoxemia).
The Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children 
(2011) named seven CCHDs as primary targets for screening: common truncus, d-
transposition of the great arteries, tetralogy of Fallot, pulmonary valve atresia, tricuspid 
valve atresia, hypoplastic left heart syndrome, and total anomalous pulmonary venous return 
(Mahle et al., 2009; Kemper et al., 2011). Other CCHDs may also be detected using pulse 
oximetry screening, but because they may not consistently have hypoxemia at or soon after 
birth, their identification would be variable and incomplete. The following CCHDs are 
Mai et al. Page 2













considered secondary targets of pulse oximetry screening: coarctation of the aorta, double 
outlet right ventricle, Ebstein anomaly, interrupted aortic arch, single ventricle, severe aortic 
stenosis and severe pulmonary stenosis (Mahle et al., 2009).
The implementation of pulse oximetry screening for CCHDs is currently underway in a few 
states, with more considering legislation and implementation (Olney and Botto, 2012). 
Surveillance case definitions, including both ICD-9-CM and CDC/BPA diagnostic codes, 
for each of the seven primary CCHD targets of pulse oximetry screening are presented in 
Appendix 2. In using these case definitions, it is important to consider as a potential 
limitation the coding system’s ability to capture cases of CCHDs. Three of the seven 
conditions (‘pulmonary valve atresia and stenosis’, ‘tricuspid valve atresia and stenosis’, and 
‘transposition of the great arteries’) include both broad codes to capture all possible cases 
that are generally collected for surveillance purpose and more refined codes that are targeted 
for newborn screening of CCHDs using pulse oximetry. For example, the surveillance 
category of ‘tricuspid valve atresia and stenosis’ encompasses both tricuspid valve atresia 
(one of the seven targeted CCHDs) as well as milder cases of tricuspid stenosis. Programs 
that are able to use more refined codes provided data separately for pulmonary valve atresia, 
tricuspid valve atresia, and d-transposition of the great arteries.
CCHD Data Presentation
Table 1 presents the counts and live birth prevalence for the seven primary targeted CCHDs 
from 34 population-based birth defects surveillance programs in the United States. Because 
pulse oximetry screening occurs in newborns, data presented in Table 1 include live births 
only; accompanying state-specific data tables available at S1-S120 include cases resulting 
from any pregnancy outcome (i.e., live births, stillbirths, and/or pregnancy terminations). 
For the three CHD diagnoses mentioned above, data are presented for both the broad 
surveillance category and the stricter definition for pulse oximetry screening.
Figure 1 presents the data from Table 1 graphically for each CCHD, grouped by the 
program’s primary case finding approach (active or passive). Three ‘central tendency 
statistics’ are presented: (1) mean prevalence defined as the arithmetic average of the 
individual program prevalences; (2) median prevalence representing the middle value of the 
individual program prevalences; and (3) pooled prevalence calculated by dividing the total 
number of cases across programs by total number of combined live births.
DISCUSSION
Variability in the observed prevalence of CCHDs across states could be due to true 
differences in prevalence; however, other reasons may account for the variability. Some 
programs could only provide data for select years. Others were unable to provide data on 
specific defects, because the conditions are not part of their program case inclusion or due to 
limitations in the coding systems. Another consideration for variability in the reported 
prevalence includes pregnancy termination practice for prenatally diagnosed cases. 
Pregnancy terminations likely vary among states based on cultural differences, race/
ethnicity, and other factors (Peller et al., 2004). Higher birth prevalence in a given state may 
reflect fewer pregnancy terminations of prenatally diagnosed cases.
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Table 1 indicates whether the program primarily used an active or passive case finding 
approach to collect the data. Case finding methodology can influence the magnitude of the 
prevalence estimates (Parker et al., 2010). Programs with active case finding generally have 
the ability to use a more refined case classification than programs with passive case finding 
that rely on ICD-9-CM codes alone; Strickland et al. (2008) demonstrated that compared to 
clinical nomenclature, ICD-9-CM coding can have relatively low sensitivity and high false-
positive fraction for some CHDs. The lack of refinement in the coding leads to the inability 
to distinguish specific CCHDs (e.g., one code for tricuspid valve atresia and stenosis instead 
of separate codes for each subtype). Programs can improve their data quality through case 
confirmation and expert case review. In addition, inclusion of pediatric cardiology centers as 
a data source can improve and refine case ascertainment (Bedard et al., 2012). Given that 
individual CCHDs are rare, missing or over-reporting even a few cases may strongly affect 
the reported prevalence. Figure 1 shows that although prevalence among the programs can 
vary greatly, the mean prevalences are similar for some CCHDs (e.g., pulmonary valve 
atresia).
CONCLUSION
As CCHD screening is being implemented across the United States, population-based birth 
defects surveillance programs can provide useful data to assist with the evaluation of CCHD 
screening by providing the ongoing and timely evidence to assess the sensitivity, specificity, 
and positive predictive value (Olney and Botto, 2012). The information gathered by birth 
defects surveillance programs could also provide an initial basis to assess outcomes, 
beginning from infant mortality and expanding, depending on a program’s ability and 
resources, to include ultimately an evaluation of the cost effectiveness of CCHD screening.
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Appendix
Table 1
ICD-9-CM and CDC/BPA Procedure Codes for 47 Birth Defects Reported in the NBDPN 
Annual Report
Birth Defects ICD-9-CM Codes CDC/BPA Codes
Central nervous system
Anencephalus 740.0–740.1 740.00–740.10









Anophthalmia/microphthalmia 743.0, 743.1 743.00–743.10
Congenital cataract 743.30–743.34 743.32
Aniridia 743.45 743.42
Ear
Anotia/microtia 744.01, 744.23 744.01, 744.21
Cardiovascular
Common truncus 745.0 745.00
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Birth Defects ICD-9-CM Codes CDC/BPA Codes
Transposition of great arteries 745.10, 745.11, 745.12, 
745.19





(Note: for CCHD screening,
only 745.10, 745.11, 745.14, 745.19)
Tetralogy of Fallot 745.2 745.20–745.21, 747.31
Ventricular septal defect 745.4 745.40–745.49 (excluding 745.487, 
745.498)
Atrial septal defect 745.5 745.51–745.59
Atrioventricular septal defect
(endocardial cushion defect)
745.60, 745.61, 745.69 745.60–745.69, 745.487
Pulmonary valve atresia and stenosis 746.01, 746.02 (Note: for
CCHD screening, 746.01 
only)
746.00–746.01 (Note: for
CCHD screening, 746.00 only)
Tricuspid valve atresia and stenosis 746.1 746.10 (excluding 746.105) (Note:
for CCHD screening, 746.10
excluding 746.105 and 746.106)
Ebstein anomaly 746.2 746.20
Aortic valve stenosis 746.3 746.30
Hypoplastic left heart syndrome 746.7 746.70
Patent ductus arteriosus 747.0 747.00
Coarctation of aorta 747.10 747.10–747.19
TAPVR 747.41 747.42
Orofacial
Cleft palate w/o cleft lip 749.0 749.00–749.09
Cleft lip with and w/o cleft palate 749.1, 749.2 749.10–749.29
Choanal atresia 748.0 748.0
Gastrointestinal
Esophageal atresia/tracheoesophageal fistula 750.3 750.30–750.35
Rectal and large intestinal atresia/stenosis 751.2 751.20–751.24
Pyloric stenosis 750.5 750.51
Hirschsprung disease (congenital megacolon) 751.3 751.30–751.34
Biliary atresia 751.61 751.65
Genitourinary
Renal agenesis/hypoplasia 753.0 753.00–753.01
Bladder exstrophy 753.5 753.50
Obstructive genitourinary defect 753.2, 753.6 753.20–753.29 and 753.60–753.69




Reduction deformity, upper limbs 755.20–755.29 755.20–755.29
Reduction deformity, lower limbs 755.30–755.39 755.30–755.39
Gastroschisis 756.79 756.71
Omphalocele 756.79 756.70
Congenital hip dislocation 754.30, 754.31, 754.35 754.30
Diaphragmatic hernia 756.6 756.61
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Birth Defects ICD-9-CM Codes CDC/BPA Codes
Chromosomal
Trisomy 13 758.1 758.10–758.19
Down syndrome 758.0 758.00–758.09
Trisomy 18 758.2 758.20–758.29
Other
Fetus or newborn affected by maternal alcohol 
use
760.71 760.71
Amniotic bands No code 658.80
ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; CDC/BPA, Centers for Disease 
Control and Prevention/British Pediatric Association; NBDPN, National Birth Defects Protection Network; w/o, without; 
CCHD, critical congenital heart defect; TAPVR, total anomalous pulmonary venous return.
Appendix
Table 2
Case Definition for the Seven Primary Targeted Critical Congenital Heart Defects
Common Truncus (Truncus 
Arteriosus or TA)
Description Failure of separation of the aorta and the pulmonary artery, resulting in a 
single







CDC/BPA codes 745.00 (remove 745.01, aortic septal defect including aorto-pulmonary 
window)
Diagnostic methods Truncus arteriosus is conclusively diagnosed only through direct visualization 
of
  the heart by cardiac imaging (typically echocardiography but also MRI),
  catheterization, surgery, or autopsy. A clinical diagnosis is considered
  insufficient to make the diagnosis.
Prenatal diagnoses not confirmed 
postnatally
These conditions may be included as cases when only diagnosed prenatally 
with
  some degree of certainty by a pediatric cardiologist through fetal
  echocardiography.




A ventricular septal defect is often present in association with truncus defects and should be coded separately.
Truncus arteriosus is one of several abnormalities of the outflow tract of the heart known as conotruncal defects. Some 
infants (1 in 5 to
  1 in 3) with these defects have an interstitial deletion on the short arm of chromosome 22 (22q11.2 deletion). This 
deletion is reliably
  diagnosed by fluorescent in situ hybridization (FISH) or microarray technology and may be missed by routine 
karyotype analysis.
Transposition of the Great Arteries (TGAs)
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Common Truncus (Truncus 
Arteriosus or TA)
Description Transposition of the aorta and the pulmonary artery such that the aorta arises
  from the right ventricle (instead of the left) and the pulmonary artery arises
  from the left ventricle (instead of the right).
Inclusions Complete transposition (dextro-TGA [d-TGA] w/o a ventricular septal defect
  [VSD]).
Corrected transposition (levo-TGA [L-TGA] (exclude for CCHD screening).
Incomplete transposition (dextro-TGA [d-TGA] with a VSD).
Transposition of the great arteries (TGAs), not otherwise specified
transposition of the great vessels (TGVs).
Exclusions N/A.
ICD-9-CM codes 745.10, 745.11, 745.12, 745.19
For CCHD screening 745.10 (d-TGA only)
CDC/BPA codes 745.10–745.19, excluding 745.13 (Double outlet right ventricle [DORV] with
  normally related great vessels), 745.15 (DORV, relationship of great vessels 
not
  specified), 745.18 (other specified TGA).
For CCHD screening 745.10 (TGA, complete, no VSD), 745.11 (TGA incomplete, with VSD), 
745.14
  (DORV with transposed great vessels), 745.19 (unspecified TGA).
Diagnostic methods d-TGA is conclusively diagnosed through direct visualization of the heart by
  cardiac echo (echocardiography), catheterization, surgery, or autopsy.
Prenatal diagnoses not confirmed 
postnatally
These conditions may be included as cases when only diagnosed prenatally 
with
  some degree of certainty by a pediatric cardiologist through fetal
  echocardiography. Live-born children who survive should always have
  confirmation of the defect postnatally.
Additional information:
d-TGA is a defect in which the right ventricle connects to the aorta and the left ventricle connects to the pulmonary 
artery (ventriculo-
  arterial discordance). An associated communication between the pulmonary and systemic circulations may be present, 
such as a
  ventricular septal defect (incomplete TGA). If a VSD is not present (intact ventricular septum) it is complete TGA. If 
the coding
  system does not include unique codes to differentiate TGA with and w/o a VSD (complete vs. incomplete), the VSD 
should be coded
  separately when present. If a communication (e.g., ASD) is created during catheterization or surgery, the ASD is not 
coded as a
  defect.
DORV is a distinct defect coded within this category. DORV can occur with normally or malposed great vessels. 
Strictly speaking, the
  great arteries in DORV cannot be transposed, and are malposed, although ICD-9 coding is limited. If a coding system 
(e.g., CDC/
  BPA), can distinguish these phenotypes, only the DORV with transposed vessels is included in the larger transposition 
category or the
  CCHD subcategory. If codes cannot distinguish phenotypes, all DORVs are included in the transposition category, but 
not CCHD
  subcategory.
L-TGA (corrected transposition) is a defect in which the right atrium connects to anatomic left ventricle (atrio-
ventricular discordance)
  and this ventricle connects to the pulmonary artery (ventriculo-arterial discordance). Because oxygen-poor blood goes 
to the lungs
  and oxygen-rich blood goes to the body, circulation is normal (corrected transposition) as long as there are no other 
defects. L-TGA is
  included in the broader transposition category for surveillance, but excluded from CCHD subcategory because it is not 
considered
  critical.
Transposition of the great arteries is one of several abnormalities of the outflow tract of the heart known as conotruncal 
defects. Very
  few infants with these defects have an interstitial deletion on the short arm of chromosome 22 (22q11.2 deletion). This 
deletion is
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Common Truncus (Truncus 
Arteriosus or TA)
  reliably diagnosed by fluorescent in situ hybridization (FISH) or microarray technology and may be missed by routine 
karyotype
  analysis.
Tetralogy of Fallot (TOF)
Description The simultaneous presence of a VSD, pulmonic and subpulmonic stenosis, a
  malpositioned aorta that overrides the ventricular septum, and right 
ventricular
  hypertrophy.
Inclusions Pentalogy of Fallot – Tetralogy of Fallot with an associated inter-atrial




Pulmonary atresia with VSD (see ‘Additional information’)
Exclusions Simultaneous occurrence of a VSD and pulmonary stenosis that has TOF
physiology but has not been diagnosed as Tetralogy of Fallot. Some coding
  systems may also include Trilogy of Fallot, or Fallot’s Triad – the 
simultaneous
  presence of an ASD, pulmonic stenosis, and right ventricular hypertrophy. 
This
  is not to be included as TOF.
ICD-9-CM codes 745.2
CDC/BPA codes 745.20–745.21, 747.31 (Note: code 746.84 has been removed)
Diagnostic methods While Tetralogy of Fallot may be suspected by clinical presentation, it may 
be
  conclusively diagnosed only through direct visualization of the heart by 
cardiac
  echo (echocardiography), catheterization, surgery, or autopsy.
Prenatal diagnoses not confirmed 
postnatally
These conditions may be included as cases when only diagnosed prenatally 
with
  some degree of certainty by a pediatric cardiologist through fetal
  echocardiography. Live-born children who survive should always have
  confirmation of the defect postnatally.
Additional information:
Tetralogy of Fallot is one of several abnormalities of the outflow tract of the heart known as conotruncal defects. Some 
infants
  (approximately 1 in 7) with this defect have an interstitial deletion on the short arm of chromosome 22 (22q11.2 
deletion). This
  deletion is reliably diagnosed by fluorescent in situ hybridization (FISH) or microarray technology and may be missed 
by routine
  karyotype analysis.
Tetralogy of Fallot is on a spectrum with other defects having important physiologic and coding differences among 
systems as seen
  here in the Table.
CCHD ICD-9 CDC/BPA
Pulmonary valve stenosis 746.02 746.01
Pulmonary atresia with intact 
ventricular septum
746.01 746.00
Pulmonary atresia with VSD (like 
Tetralogy of Fallot)
– 747.31
Tetralogy of Fallot 745.2 745.20–21
Pulmonary atresia with a VSD is similar to severe forms of Tetralogy of Fallot and is included for surveillance. There is 
no specific code
  depicting valvular pulmonary atresia with VSD; hence in CDC/BPA the code 747.31 (‘pulmonary artery atresia with 
septal defect’) is
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Common Truncus (Truncus 
Arteriosus or TA)
  used. For pulmonary valvular atresia w/o a VSD (intact ventricular septum), the code 746.00 (‘atresia, hypoplasia of 
pulmonary
  valve’) is used – see separate section on Pulmonary valve atresia/stenosis.
Pulmonary valve atresia and stenosis
Description Pulmonary valve atresia – Lack of patency, or failure of formation altogether, 
of
  the pulmonary valve, resulting in obstruction of blood flow from the right
  ventricle to the pulmonary artery.
Pulmonary valve stenosis – Obstruction or narrowing of the pulmonary valve,
  which may impair blood flow in varying degrees of severity from the right
  ventricle to the pulmonary artery.
Inclusions Pulmonary valve atresia with intact ventricular septum.
Pulmonary valve stenosis (PS) (most cases of PS).
Pulmonic stenosis (PS – valve not specified).
Exclusions Atresia or stenosis of the main or branch (right or left) pulmonary arteries, not
  involving the pulmonary valve.
Pulmonary stenosis that occurs as part of Tetralogy or Pentalogy of Fallot.
Supra-valvular or sub-valvular pulmonic stenosis.
ICD-9-CM codes 746.01 (Pulmonary atresia), 746.02 (pulmonary valve stenosis).
For CCHD screening 746.01 only (pulmonary atresia, intact ventricular septum).
CDC/BPA codes 746.00 (pulmonary valve atresia), 746.01 (pulmonary valve stenosis).
For CCHD screening 746.00 only (pulmonary atresia, intact ventricular septum).
Diagnostic methods Although pulmonary valve atresia or stenosis may be suspected by clinical
  presentation, it may be conclusively diagnosed only through direct 
visualization
  of the heart by cardiac echo (echocardiography), catheterization, surgery, or
  autopsy.
Prenatal diagnoses not confirmed 
postnatally
Although these conditions may be identified by prenatal ultrasound, they 
should
  not be included in surveillance data w/o postnatal confirmation. In addition, 
the
  absence of pulmonary valve atresia or stenosis on prenatal ultrasound does 
not
  necessarily mean that it will not be diagnosed after delivery.
Additional information:
These defects have important physiologic and coding differences among systems as seen here in the Table, which is also 
discussed in
  the Tetralogy of Fallot section.
CCHD ICD-9 CDC/BPA
Pulmonary valve stenosis 746.02 746.01
Pulmonary atresia with intact 
ventricular septum
746.01 746.00
Pulmonary atresia with VSD (like 
Tetralogy of Fallot)
– 747.31
Tetralogy of Fallot 745.2 745.20–21
Pulmonary valve atresia or stenosis may occur with or w/o a coexisting ventricular septal defect. For pulmonary valve 
atresia w/o a
  VSD (intact ventricular septum), the CDC/BPA code 746.00 (“atresia, hypoplasia of pulmonary valve”) is used, 
corresponding to the
  ICD-9-CM code 746.01. However, in CDC/BPA, 746.01 refers to pulmonary valve stenosis.
Pulmonary atresia with a VSD is similar to severe forms of Tetralogy of Fallot, and is included with Tetralogy of Fallot 
for surveillance.
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Common Truncus (Truncus 
Arteriosus or TA)
  There is no specific code depicting valvular pulmonary atresia with VSD; hence in CDC/BPA the code 747.31 
(‘pulmonary artery
  atresia with septal defect’) is used. If a case has codes for both Pulmonary atresia and Tetralogy of Fallot, it should be 
counted as
  Tetralogy of Fallot.
Tricuspid valve atresia and stenosis
Description Tricuspid valve atresia – Lack of patency, or failure of formation altogether, 
of the
  tricuspid valve, resulting in obstruction of blood flow from the right atrium 
to
  the right ventricle.
Tricuspid valve stenosis – Obstruction or narrowing of the tricuspid valve, 
which
  may impair blood flow from the right atrium to the right ventricle.
Inclusions Tricuspid atresia.
Tricuspid stenosis.
Exclusions Tricuspid regurgitation w/o specific mention of tricuspid atresia or stenosis.
ICD-9-CM codes 746.1
CDC/BPA codes 746.100 (tricuspid atresia), 746.106 (tricuspid stenosis) (excluding 746.105 –
  tricuspid insufficiency).
For CCHD screening 746.100 only.
Note: Only the tricuspid atresia is a CCHD. Many cases of tricuspid stenosis 
are
  not critical.
Diagnostic methods Although tricuspid valve atresia or stenosis may be suspected by clinical
  presentation, it may be conclusively diagnosed only through direct 
visualization
  of the heart by cardiac echo (echocardiography), catheterization, surgery, or
  autopsy.
Prenatal diagnoses not confirmed 
postnatally
Although these conditions may be identified by prenatal ultrasound, they 
should
  not be included in surveillance data w/o postnatal confirmation. In addition, 
the
  absence of tricuspid valve atresia or stenosis on prenatal ultrasound does not
  necessarily mean that it will not be diagnosed after delivery.
Additional information:
In the ICD-9-CM coding system, it is impossible to distinguish mild cases of tricuspid stenosis, from the critical CHD 
of tricuspid
atresia. Reports using only the code 745.1 (ICD-9-CM) may include both defects, and therefore may not be an accurate 
estimate of the
number of cases of either defect individually.
Hypoplastic left heart syndrome (HLHS)
Description A condition in which the structures on the left side of the heart and the aorta 
are
extremely small. Classically, this condition includes hypoplasia of the left
ventricle, atresia, or severe hypoplasia of both the mitral and aortic valves,
hypoplasia of the aortic arch, and coarctation of the aorta.
Inclusions Any diagnosis of hypoplastic left heart syndrome, regardless of whether all
conditions in the classic definition are present.
Exclusions Hypoplasia or diminished size of the left ventricle alone w/o involvement of 
other
structures on the left side of the heart or the aorta.
Hypoplastic left heart or small left ventricle that occurs as part of another 
complex
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Common Truncus (Truncus 
Arteriosus or TA)
heart defect, such as an endocardial cushion defect (“unbalanced” AV canal).
ICD-9-CM codes 746.7
CDC/BPA codes 746.70
Diagnostic methods Although hypoplastic left heart may be suspected by clinical presentation,
examination, and echocardiogram (EKG) changes, it may be conclusively
diagnosed only through direct visualization of the heart by cardiac echo
(echocardiography), catheterization, surgery, or autopsy.
Prenatal diagnoses not confirmed 
postnatally
These conditions may be included as cases when only diagnosed prenatally 
with
some degree of certainty by a pediatric cardiologist through fetal
echocardiography. Live-born children who survive should always have
confirmation of the defect postnatally.
Total anomalous pulmonary venous return (TAPVR)
Description A condition in which all four pulmonary veins connect anomalously into the
systemic venous circulation to the right atrium or the body (systemic veins)
instead of the left atrium; often occurs with other cardiac defects.
Inclusions TAPVR (total anomalous pulmonary venous return).
TAPVC (total anomalous pulmonary venous connection).
TAPVD (total anomalous pulmonary venous drainage).
Exclusions If not all 4 veins are visibly connecting/draining anomalously (e.g., Partial
Anomalous Venous Return, ICD-9-CM code 747.42).
ICD-9-CM codes 747.41
CDC/BPA codes 747.42
Diagnostic methods Although TAPVR may be suspected by clinical presentation, it may be
conclusively diagnosed only through direct visualization of the heart by 
cardiac
echo (echocardiography), catheterization, surgery, or autopsy. The difficulty 
in
viewing all four veins may mean that several echocardiograms may be needed 
to
confirm the diagnosis.
Prenatal diagnoses not confirmed 
postnatally
TAPVR is difficult to identify prenatally. If identified by prenatal ultrasound, 
it
should not be included in surveillance data w/o postnatal confirmation. In
addition, the absence of TAPVR on prenatal ultrasound does not necessarily 
mean
that it will not be diagnosed after delivery.
Additional information:
Total anomalous pulmonary venous return and partial anomalous pulmonary venous return have not been shown to be
developmentally related, although they share a similar description. Also, there are subtle differences in the meaning of 
anomalous
venous connection, return, and drainage, but the terms are often used interchangeably.
ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; CDC/BPA Codes, Centers for 
Disease Control
and Prevention/British Pediatric Association Classification of Diseases; w/o, without; CCHD, critical congenital heart 
defect; N/A, not
applicable; ASD, atrial septal defect.
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Critical congenital heart defects targeted for newborn screening: prevalence among live 
births by U.S. population-based surveillance programs.
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